search buttonmobile navigation expand button

Need Assistance?












Back to Search Results

NRG-BR003

Title
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Description
The purpose of this study is to compare the good and bad effects of the chemotherapy drug, Carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without Carboplatin.  The addition of Carboplatin to the usual chemotherapy could prevent cancer from returning, but it could also cause side effects.  This study will allow the researchers to know whether giving Carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy.  If giving Carboplatin with the usual chemotherapy drugs is better, there should be a higher chance that breast cancer will not return.  Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread, but it has not yet been proven useful in earlier stages of breast cancer. 
Trial Information
Principal Investigator: Dr. Michael Simon, MD

Contact: Study Coordinator
Phone (Main): 313-576-9385

IRB Number: 2016-00030
clinicaltrials.gov: 82488967

More Information: